Page last updated: 2024-10-29

ifosfamide and Metastase

ifosfamide has been researched along with Metastase in 176 studies

Research Excerpts

ExcerptRelevanceReference
"High-dose methotrexate (HD-MTX) is recognized as an efficient component of therapy against pediatric osteosarcoma in combination with other drugs such as cisplatin (CDP), carboplatin (CBDCA), doxorubicin (ADM), etoposide (VP-16) and ifosfamide (IFO)."9.19Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience. ( Anurathapan, U; Choeyprasert, W; Chuansumrit, A; Hongeng, S; Nartthanarung, A; Pakakasama, S; Sirachainan, N; Songdej, D, 2014)
"The EICESS-92 Trial compared the efficacy of cyclophosphamide and ifosfamide in patients with Ewing sarcoma."9.14Chemotherapy: The role of ifosfamide and etoposide in Ewing sarcoma. ( DuBois, SG; Grier, HE, 2009)
"The aim of this study was to evaluate the maximum tolerated dose (MTD) and safety of the combination of non- pegylated liposomal doxorubicin (Myocet) and ifosfamide in patients with metastatic soft tissue sarcomas."9.14Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas. ( Barbato, A; Bertuzzi, A; Di Comite, G; Lutman, RF; Mussi, C; Santoro, A; Stroppa, E, 2010)
"High-dose ifosfamide plus doxorubicin is an active regimen for all subtypes of gynecological sarcomas."9.12Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. ( Cerny, T; Dietrich, D; Fey, M; Honegger, HP; Jundt, G; Leyvraz, S; Lissoni, A; Sessa, C; Zweifel, M, 2006)
"This phase I study evaluated the toxicity of first-line combined pegylated liposomal doxorubicin (Caelyx) and ifosfamide in patients with advanced and/or metastatic soft tissue sarcomas."9.12Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. ( Blay, J; Christensen, TB; Daugaard, S; Hermans, C; Judson, I; Marreaud, S; Nielsen, OS; Pink, D; Reichardt, P; van Glabbeke, M, 2006)
"The established clinical activity of docetaxel and ifosfamide as single agents in anthracycline pre-treated breast cancer, led us to conduct a phase I-II study to define the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and clinical activity of the docetaxel+ifosfamide combination in this setting."9.12Docetaxel-ifosfamide combination in patients with advanced breast cancer failing prior anthracycline-based regimens: results of a phase I-II study. ( Gassiamis, A; Karabelis, A; Kosmas, C; Malamos, N; Mylonakis, N; Polyzos, A; Skopelitis, H; Tsakonas, G; Tsavaris, N, 2007)
"To study the role of single agent carboplatin chemotherapy in patients with metastatic seminoma based on the data from two randomised trials."9.11Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. ( Bokemeyer, C; Clemm, C; Gerl, A; Hartmann, JT; Horwich, A; Kanz, L; Kollmannsberger, C; Meisner, C; Oliver, T; Rückerl, CP; Schmoll, HJ; Stenning, S, 2004)
"The objectives of this trial were to estimate the response rate, progression-free survival, and overall survival of patients who received therapy with etoposide and high-dose ifosfamide, and to define the toxicity of this combination when provided with standard chemotherapy in patients with newly diagnosed metastatic osteosarcoma."9.10Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. ( Bernstein, M; Devidas, M; Ferguson, W; Gebhardt, MC; Goorin, AM; Grier, HE; Harris, MB; Link, M; Schwartz, CL; Siegal, GP, 2002)
"A prospective trial to evaluate the efficacy and toxicity of ifosfamide (IFX) and vinorelbine (VNB) in patients with prior anthracycline therapy for metastatic breast cancer (MBC) was conducted."9.09Ifosfamide and vinorelbine in metastatic breast cancer in patients with prior anthracycline therapy. ( Aziz, Z; Qazi, S; Rehman, A, 1999)
"Forty-six patients were included in a phase II study to evaluate the response rate and toxicity of a combination of ifosfamide and vinorelbine in metastatic breast cancer patients previously treated with one or more regimens of chemotherapy."9.09Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy. ( Albistur, JJ; Barnadas, A; Constenla, M; Estévez, LG; Frau, A; Lizón, J; Lobo, F; Martínez, P; Méndez, M; Provencio, M; Sánchez, MJ, 1999)
"Patients with locally advanced or metastatic soft tissue sarcoma refractory to treatment with anthracyclines and ifosfamide were enrolled into the present phase II study."9.09Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. ( Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC, 2001)
" ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma."9.09Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. ( Breitfeld, PP; Crist, WM; Donaldson, SS; Lobe, T; Lyden, E; Maurer, HM; Raney, RB; Ruymann, FB; Teot, LA; Wharam, M, 2001)
"Twenty patients with locally advanced or metastatic breast cancer were treated with four cycles of ifosfamide/mesna 5 g m-2 and epirubicin 60 mg m-2 every 14 days with granulocyte colony-stimulating factor (G-CSF, Filgrastim)."9.08The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer. ( Calvert, AH; Cantwell, BM; Chapman, F; Gumbrell, L; Lind, MJ; McCann, E; Middleton, I; Millward, MJ; Proctor, M; Simmonds, D, 1995)
"We conducted a phase I/II trial to investigate the activity of ifosfamide/carboplatin/etoposide given over 2 or 3 days (mini-ICE) to patients with anthracycline-refractory or recurrent metastatic breast cancer."9.08Ifosfamide/carboplatin/etoposide chemotherapy for metastatic breast cancer with or without autologous hematopoietic stem cell transplantation: evaluation of dose-response relationships. ( Elfenbein, GJ; Fields, KK; Perkins, JB, 1995)
"This study was designed to test if the activity of a phase II agent, ifosfamide, would have been underestimated if it was tested exclusively in a population of children and young adults with recurrent osteosarcoma."9.08Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. ( Ayala, AG; Cantor, AB; Ferguson, WS; Goorin, AM; Harris, MB; Holbrook, T; Link, MP; Shochat, SJ, 1995)
"Ifosfamide is an oxazaphosphorine analogue of cyclophosphamide with proven activity in breast cancer but substantial urotoxicity."9.08Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer. ( Hartmann, LC; Ingle, JN; Krook, JE; Mailliard, JA; Wieand, HS, 1995)
"To determine the effectiveness and toxicity of ifosfamide chemotherapy in women with metastatic or recurrent endometrial stromal sarcomas unexposed to other chemotherapy."9.08Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group. ( Blessing, JA; DiSaia, PJ; Park, R; Rosenshein, N; Sutton, G, 1996)
"In a randomized, phase II trial, we evaluated the effectiveness of continued chemotherapy with epirubicin/ ifosfamide versus unmaintained treatment interruption in advanced metastatic breast cancer."9.08Epirubicin and ifosfamide in metastatic breast cancer. ( Bartels, H; Becher, R; DeDycker, R; Fischedick, AR; Halabi, S; Hartwich, G; Hawig, I; Hayungs, J; Hering, KG; Hirche, H; Höfeler, H; Huhn, R; Illiger, HJ; Kloke, O; Ohl, S; Pielken, HJ; Rieche, K; Seeber, S; Szanto, J; Wolf, E, 1996)
"To evaluate the efficacy and toxicity of the combination of ifosfamide (IFX) and vinorelbine (VNB) as first-line chemotherapy in metastatic breast cancer (MBC)."9.08Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer. ( Acuña, JM; Acuña, LA; Amato, S; Barbieri, MR; Cuevas, MA; Dominguez, ME; Lacava, JA; Langhi, MJ; Leone, BA; Machiavelli, MR; Ortiz, EH; Perez, JE; Rodriguez, R; Romero, AO; Sabatini, CL; Salvadori, MA; Vallejo, CT, 1996)
"The new combination of ifosfamide and vinorelbine was evaluated in a phase II study of patients with metastatic breast cancer."9.08Phase II study of vinorelbine and ifosfamide in anthracycline resistant metastatic breast cancer. ( Cafiero, F; Gipponi, M; Landucci, M; Pronzato, P; Queirolo, P; Vaira, F; Vigani, A, 1997)
"The aim of this paper is to evaluate the activity of ifosfamide in previously treated patients with metastatic breast cancer."9.08Phase II study of ifosfamide and mesna in patients with metastatic breast cancer. ( Esparza-Guerra, L; Holmes, FA; Hortobagyi, GN; Valero, V; Walters, RS, 1998)
"A combination of 5-fluorouracil (5-FU), adriamycin, and cyclophosphamide (FAC) was compared to a combination of 5-FU, adriamycin, and ifosfamide (FAI) in the treatment of metastatic breast cancer."9.04Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. ( Blumenschein, GR; Bodey, GP; Buzdar, AU; Hersh, EM; Hortobagyi, GN; Legha, SS; Tashima, CK; Yap, HY, 1979)
"This meta-analysis examines the role of ifosfamide-based combination chemotherapy in patients with advanced soft tissue sarcoma."8.84Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. ( Blackstein, M; Haynes, AE; Stys-Norman, D; Verma, S; Younus, J, 2008)
"A retrospective study was performed to assess toxicity and response rate of ifosfamide salvage treatment for dogs diagnosed with metastatic osteosarcoma (OSA)."7.80Evaluation of ifosfamide salvage therapy for metastatic canine osteosarcoma. ( Batschinski, K; Dervisis, NG; Kitchell, BE, 2014)
"We evaluated the efficacy and tolerability of combined paclitaxel and ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer (MBC)."7.76Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance. ( Chang, H; Choi, HJ; Chung, HC; Kim, JH; Kim, SI; Kim, YT; Koo, JS; Moon, YW; Park, BW; Park, S; Roh, JK; Sohn, JH, 2010)
"The efficacy of zoledronic acid (ZOL), with or without the anticancer drug ifosfamide (IFO), was tested on primary bone tumor growth using a rat-transplantable model of osteosarcoma."7.73Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. ( Blanchard, F; Charrier, C; Coipeau, P; Couillaud, S; Gouin, F; Heymann, D; Heymann, MF; Ory, B; Redini, F; Thiery, JP, 2005)
"Ifosfamide is a leading drug in soft tissue sarcoma therapy."7.70Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. ( Bergnolo, P; Boglione, A; Bumma, C; Colussi, AM; Comandone, A; Dal Canton, O; Frustaci, S; Leone, L; Monteleone, M; Oliva, C, 1998)
"25 previously untreated patients with inoperable or metastatic adenocarcinoma of the oesophagus or oesophageal-gastric junction area were treated with ifosfamide 6 g/m2 over 48 hours, combined with mesna 6 g/m2."7.68Ifosfamide in advanced adenocarcinoma of the oesophagus or oesophageal-gastric junction area. Rotterdam Esophageal Tumor Study Group. ( Kok, TC; Splinter, TA; Tilanus, HW; van der Gaast, A, 1991)
"The combination of ifosfamide (IFO) and epirubicin (EPI) has been found to be an effective regimen in the treatment of metastatic tumours and shows remarkable activity in heavily pretreated breast cancer patients."7.68Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours. ( Hoffmann, W; Könner, J; Migeod, F; Seeber, S; Weidmann, B, 1990)
"Thirty-seven patients with widely metastatic malignant melanoma were treated with one of three chemotherapy regimens, incorporating high-dose dacarbazine (DTIC)."7.67High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. ( Carr, T; Chadwick, G; Craig, P; Jones, R; Lind, M; Morgenstern, G; Thatcher, D, 1989)
"Ifosfamide was tested in a phase II study in 12 evaluable patients with advanced malignant melanoma."7.67Phase II study with ifosfamide in advanced malignant melanoma. ( Bajetta, E; Bonfante, V; Ferrari, L; Negretti, E, 1988)
"Fifty-three patients with inoperable non-small cell bronchial carcinoma were treated at four-weekly intervals with two cytostatic drugs, doxorubicin (50 mg/m2 on day 1) and ifosfamide (2000 mg/m2 on days 1-3)."7.66[Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide]. ( Göbel, D; Matthiessen, W; Stempinski, E; Thalmann, U, 1983)
"" The regimen included an intensification of ifosfamide dosing from 1,800 mg/m(2) /day × 5 days per cycle to 2,800 mg/m(2) /day × 5 days per cycle."6.80Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma. ( Chou, AJ; Goodbody, CM; Magnan, H; Pratilas, CA; Riedel, E; Wexler, LH, 2015)
" Ifosfamide with G-CSF in combination with doxorubicin or paclitaxel achieves effective mobilization of PBPC and anti-tumor activity with minimal toxicity."6.69Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer. ( Brettell, M; Briggs, P; Chapple, P; Francis, P; Gardyn, J; Gates, P; Januszewicz, EH; Juneja, S; Millward, MJ; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Toner, GC; Wolf, M, 1999)
"Twenty-five patients with metastatic breast cancer were treated with ICE after failure of previous chemotherapy."6.69Ifosfamide, carboplatin and etoposide (ICE) in metastatic and refractory breast cancer. ( Asbury, R; Boros, L; Chang, AY; Garrow, G; Hui, L; Rubins, J, 1999)
"Patients with metastatic breast cancer refractory to all standard dose therapy were treated with escalating doses of mitoxantrone (45 to 105 mg/m2) and thiotepa (900 to 1,350 mg/m2) followed by autologous stem cell rescue."6.67Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities. ( Ballester, OF; Elfenbein, GJ; Fields, KK; Foody, MC; Hiemenz, JW; Janssen, WE; Kronish, LE; Perkins, JB; Zorsky, PE, 1993)
"Doxorubicin, the most active agent for breast cancer, was studied first."6.39Paclitaxel combination therapy in the treatment of metastatic breast cancer. ( Holmes, FA, 1996)
"Metastases from cystosarcoma phyllodes are rare, and treatment generally is ineffective."6.38Ifosfamide is an active drug for chemotherapy of metastatic cystosarcoma phyllodes. ( Fisher, C; Hawkins, RE; McKinna, JA; Schofield, JB; Wiltshaw, E, 1992)
"Ifosfamide is an alkylating agent with well-demonstrated efficacy against STS, and dose-dependent activity."5.37High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients. ( Baek, KK; Chang, MH; Han, B; Lee, J; Lee, SH; Lim, T; Park, JO, 2011)
"Between 1982 and 1986, 38 patients with soft tissue sarcomas were treated with a combination of ADM/DTIC (group A), another 45 (group B) received ADM/IFO between 1986 and 1990."5.28Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide. ( Dietel, M; Hossfeld, DK; Schwarz, R; Weh, HJ; Wingberg, D; Zornig, C; Zügel, M, 1990)
"Ifosfamide (Z 4942) is an alkylating agent with the structure of a cyclophosphamide analog."5.27[Treatment of pain caused by metastases of reactivated prostatic cancer with ifosfamide]. ( Kawai, T; Kihara, K; Sakuramoto, T; Satomi, Y; Takeda, T, 1983)
"Patients with high-grade soft tissue sarcomas were treated with 2 cycles of ifosfamide, mitomycin, doxorubicin, and cisplatin plus GM-CSF subcutaneous followed by 45 Gy irradiation with concurrent 2 cycles of mitomycin, doxorubicin, and cisplatin followed by surgery +/- intraoperative radiation or brachytherapy."5.22Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation GM-CSF During Preoperative Irradiation and Postoperatively. ( Haddock, M; Mahoney, M; Maples, W; Markovic, SN; O'Connor, MI; Okuno, S; Petersen, I; Shives, T; Sim, F, 2016)
"High-dose methotrexate (HD-MTX) is recognized as an efficient component of therapy against pediatric osteosarcoma in combination with other drugs such as cisplatin (CDP), carboplatin (CBDCA), doxorubicin (ADM), etoposide (VP-16) and ifosfamide (IFO)."5.19Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience. ( Anurathapan, U; Choeyprasert, W; Chuansumrit, A; Hongeng, S; Nartthanarung, A; Pakakasama, S; Sirachainan, N; Songdej, D, 2014)
"The EICESS-92 Trial compared the efficacy of cyclophosphamide and ifosfamide in patients with Ewing sarcoma."5.14Chemotherapy: The role of ifosfamide and etoposide in Ewing sarcoma. ( DuBois, SG; Grier, HE, 2009)
"The aim of this study was to evaluate the maximum tolerated dose (MTD) and safety of the combination of non- pegylated liposomal doxorubicin (Myocet) and ifosfamide in patients with metastatic soft tissue sarcomas."5.14Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas. ( Barbato, A; Bertuzzi, A; Di Comite, G; Lutman, RF; Mussi, C; Santoro, A; Stroppa, E, 2010)
"Dynamic PET studies with (18)F-FDG were performed in patients with metastatic soft tissue sarcomas who received conventional chemotherapy with doxorubicin hydrochloride (Adriamycin) and ifosfamide (AI-G)."5.14Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis. ( Dimitrakopoulou-Strauss, A; Egerer, G; Haberkorn, U; Kasper, B; Schmitt, T; Strauss, LG; Vasamiliette, J, 2010)
"High-dose ifosfamide plus doxorubicin is an active regimen for all subtypes of gynecological sarcomas."5.12Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. ( Cerny, T; Dietrich, D; Fey, M; Honegger, HP; Jundt, G; Leyvraz, S; Lissoni, A; Sessa, C; Zweifel, M, 2006)
"This phase I study evaluated the toxicity of first-line combined pegylated liposomal doxorubicin (Caelyx) and ifosfamide in patients with advanced and/or metastatic soft tissue sarcomas."5.12Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. ( Blay, J; Christensen, TB; Daugaard, S; Hermans, C; Judson, I; Marreaud, S; Nielsen, OS; Pink, D; Reichardt, P; van Glabbeke, M, 2006)
"The established clinical activity of docetaxel and ifosfamide as single agents in anthracycline pre-treated breast cancer, led us to conduct a phase I-II study to define the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and clinical activity of the docetaxel+ifosfamide combination in this setting."5.12Docetaxel-ifosfamide combination in patients with advanced breast cancer failing prior anthracycline-based regimens: results of a phase I-II study. ( Gassiamis, A; Karabelis, A; Kosmas, C; Malamos, N; Mylonakis, N; Polyzos, A; Skopelitis, H; Tsakonas, G; Tsavaris, N, 2007)
"Adding ifosfamide and etoposide to standard therapy does not improve outcomes of patients with Ewing's sarcoma or PNET of bone with metastases at diagnosis."5.11Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study. ( Dickman, PS; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Moore, S; Perlman, EJ; Pritchard, DJ; Rausen, AR; Tarbell, NJ; Vietti, TJ, 2004)
"To study the role of single agent carboplatin chemotherapy in patients with metastatic seminoma based on the data from two randomised trials."5.11Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. ( Bokemeyer, C; Clemm, C; Gerl, A; Hartmann, JT; Horwich, A; Kanz, L; Kollmannsberger, C; Meisner, C; Oliver, T; Rückerl, CP; Schmoll, HJ; Stenning, S, 2004)
"The objectives of this trial were to estimate the response rate, progression-free survival, and overall survival of patients who received therapy with etoposide and high-dose ifosfamide, and to define the toxicity of this combination when provided with standard chemotherapy in patients with newly diagnosed metastatic osteosarcoma."5.10Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. ( Bernstein, M; Devidas, M; Ferguson, W; Gebhardt, MC; Goorin, AM; Grier, HE; Harris, MB; Link, M; Schwartz, CL; Siegal, GP, 2002)
"A prospective trial to evaluate the efficacy and toxicity of ifosfamide (IFX) and vinorelbine (VNB) in patients with prior anthracycline therapy for metastatic breast cancer (MBC) was conducted."5.09Ifosfamide and vinorelbine in metastatic breast cancer in patients with prior anthracycline therapy. ( Aziz, Z; Qazi, S; Rehman, A, 1999)
"Forty-six patients were included in a phase II study to evaluate the response rate and toxicity of a combination of ifosfamide and vinorelbine in metastatic breast cancer patients previously treated with one or more regimens of chemotherapy."5.09Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy. ( Albistur, JJ; Barnadas, A; Constenla, M; Estévez, LG; Frau, A; Lizón, J; Lobo, F; Martínez, P; Méndez, M; Provencio, M; Sánchez, MJ, 1999)
"Twenty-four children and adolescents with metastatic sarcomas received VACIME chemotherapy, consisting of eight courses of vincristine 2 mg/m(2) on day 0; doxorubicin 20 mg/m(2)/day on days 0-3; cyclophosphamide 360 mg/m(2)/day on days 0-4; ifosfamide 1,800 mg/m(2)/day on days 0-4; mesna 2,400 mg/m(2)/day; and etoposide 100 mg/m(2)/day on days 0-4."5.09Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas. ( Conrad, EU; Felgenhauer, J; Hawkins, D; Lindsley, K; Miser, JS; Pendergrass, T, 2000)
"Patients with locally advanced or metastatic soft tissue sarcoma refractory to treatment with anthracyclines and ifosfamide were enrolled into the present phase II study."5.09Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. ( Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC, 2001)
" ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma."5.09Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. ( Breitfeld, PP; Crist, WM; Donaldson, SS; Lobe, T; Lyden, E; Maurer, HM; Raney, RB; Ruymann, FB; Teot, LA; Wharam, M, 2001)
"Twenty patients with locally advanced or metastatic breast cancer were treated with four cycles of ifosfamide/mesna 5 g m-2 and epirubicin 60 mg m-2 every 14 days with granulocyte colony-stimulating factor (G-CSF, Filgrastim)."5.08The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer. ( Calvert, AH; Cantwell, BM; Chapman, F; Gumbrell, L; Lind, MJ; McCann, E; Middleton, I; Millward, MJ; Proctor, M; Simmonds, D, 1995)
"We conducted a phase I/II trial to investigate the activity of ifosfamide/carboplatin/etoposide given over 2 or 3 days (mini-ICE) to patients with anthracycline-refractory or recurrent metastatic breast cancer."5.08Ifosfamide/carboplatin/etoposide chemotherapy for metastatic breast cancer with or without autologous hematopoietic stem cell transplantation: evaluation of dose-response relationships. ( Elfenbein, GJ; Fields, KK; Perkins, JB, 1995)
"This study was designed to test if the activity of a phase II agent, ifosfamide, would have been underestimated if it was tested exclusively in a population of children and young adults with recurrent osteosarcoma."5.08Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. ( Ayala, AG; Cantor, AB; Ferguson, WS; Goorin, AM; Harris, MB; Holbrook, T; Link, MP; Shochat, SJ, 1995)
"Ifosfamide is an oxazaphosphorine analogue of cyclophosphamide with proven activity in breast cancer but substantial urotoxicity."5.08Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer. ( Hartmann, LC; Ingle, JN; Krook, JE; Mailliard, JA; Wieand, HS, 1995)
"To determine the effectiveness and toxicity of ifosfamide chemotherapy in women with metastatic or recurrent endometrial stromal sarcomas unexposed to other chemotherapy."5.08Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group. ( Blessing, JA; DiSaia, PJ; Park, R; Rosenshein, N; Sutton, G, 1996)
"In a randomized, phase II trial, we evaluated the effectiveness of continued chemotherapy with epirubicin/ ifosfamide versus unmaintained treatment interruption in advanced metastatic breast cancer."5.08Epirubicin and ifosfamide in metastatic breast cancer. ( Bartels, H; Becher, R; DeDycker, R; Fischedick, AR; Halabi, S; Hartwich, G; Hawig, I; Hayungs, J; Hering, KG; Hirche, H; Höfeler, H; Huhn, R; Illiger, HJ; Kloke, O; Ohl, S; Pielken, HJ; Rieche, K; Seeber, S; Szanto, J; Wolf, E, 1996)
"To evaluate the efficacy and toxicity of the combination of ifosfamide (IFX) and vinorelbine (VNB) as first-line chemotherapy in metastatic breast cancer (MBC)."5.08Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer. ( Acuña, JM; Acuña, LA; Amato, S; Barbieri, MR; Cuevas, MA; Dominguez, ME; Lacava, JA; Langhi, MJ; Leone, BA; Machiavelli, MR; Ortiz, EH; Perez, JE; Rodriguez, R; Romero, AO; Sabatini, CL; Salvadori, MA; Vallejo, CT, 1996)
"The new combination of ifosfamide and vinorelbine was evaluated in a phase II study of patients with metastatic breast cancer."5.08Phase II study of vinorelbine and ifosfamide in anthracycline resistant metastatic breast cancer. ( Cafiero, F; Gipponi, M; Landucci, M; Pronzato, P; Queirolo, P; Vaira, F; Vigani, A, 1997)
"The aim of this paper is to evaluate the activity of ifosfamide in previously treated patients with metastatic breast cancer."5.08Phase II study of ifosfamide and mesna in patients with metastatic breast cancer. ( Esparza-Guerra, L; Holmes, FA; Hortobagyi, GN; Valero, V; Walters, RS, 1998)
" Those with high volume metastases will receive either BEP or etoposide, ifosfamide and cisplatinum (VIP)."5.06Potential advances in combination chemotherapy for advanced testicular cancer. ( Boven, E; De Pauw, M; Harris, A; Jones, W; Kaye, SB; Sleijfer, D; Splinter, T; Stoter, G; Ten Bokkel Huinink, W; Van Oosterom, A, 1988)
"A combination of 5-fluorouracil (5-FU), adriamycin, and cyclophosphamide (FAC) was compared to a combination of 5-FU, adriamycin, and ifosfamide (FAI) in the treatment of metastatic breast cancer."5.04Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. ( Blumenschein, GR; Bodey, GP; Buzdar, AU; Hersh, EM; Hortobagyi, GN; Legha, SS; Tashima, CK; Yap, HY, 1979)
"This meta-analysis examines the role of ifosfamide-based combination chemotherapy in patients with advanced soft tissue sarcoma."4.84Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. ( Blackstein, M; Haynes, AE; Stys-Norman, D; Verma, S; Younus, J, 2008)
"5%) nonmetastatic soft tissue sarcoma received neoadjuvant chemoradiotherapy with ifosfamide (1."3.83Effective local control of advanced soft tissue sarcoma with neoadjuvant chemoradiotherapy and surgery: A single institutional experience. ( Agaimy, A; Croner, R; Fietkau, R; Hohenberger, W; Lettmaier, S; Ott, O; Semrau, S; Stubbe, F; Vassos, N, 2016)
"A retrospective study was performed to assess toxicity and response rate of ifosfamide salvage treatment for dogs diagnosed with metastatic osteosarcoma (OSA)."3.80Evaluation of ifosfamide salvage therapy for metastatic canine osteosarcoma. ( Batschinski, K; Dervisis, NG; Kitchell, BE, 2014)
"We evaluated the efficacy and tolerability of combined paclitaxel and ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer (MBC)."3.76Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance. ( Chang, H; Choi, HJ; Chung, HC; Kim, JH; Kim, SI; Kim, YT; Koo, JS; Moon, YW; Park, BW; Park, S; Roh, JK; Sohn, JH, 2010)
"The efficacy of zoledronic acid (ZOL), with or without the anticancer drug ifosfamide (IFO), was tested on primary bone tumor growth using a rat-transplantable model of osteosarcoma."3.73Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. ( Blanchard, F; Charrier, C; Coipeau, P; Couillaud, S; Gouin, F; Heymann, D; Heymann, MF; Ory, B; Redini, F; Thiery, JP, 2005)
"Twenty-three children and adolescents with metastatic sarcomas received vincristine, doxorubicin, cyclophosphamide, ifosfamide, sodium mercaptoethanesulfonate (mensa), and etoposide (VACIME) chemotherapy, consisting of 8 courses of vincristine 2 mg/m(2) on Day 0, doxorubicin 37."3.71Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. ( Douglas, J; Felgenhauer, J; Gooley, T; Hawkins, DS; Kreissman, S; Park, J; Pendergrass, TW; Rowley, SD; Sanders, JE; Thomson, B, 2002)
"Ifosfamide is a leading drug in soft tissue sarcoma therapy."3.70Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. ( Bergnolo, P; Boglione, A; Bumma, C; Colussi, AM; Comandone, A; Dal Canton, O; Frustaci, S; Leone, L; Monteleone, M; Oliva, C, 1998)
"25 previously untreated patients with inoperable or metastatic adenocarcinoma of the oesophagus or oesophageal-gastric junction area were treated with ifosfamide 6 g/m2 over 48 hours, combined with mesna 6 g/m2."3.68Ifosfamide in advanced adenocarcinoma of the oesophagus or oesophageal-gastric junction area. Rotterdam Esophageal Tumor Study Group. ( Kok, TC; Splinter, TA; Tilanus, HW; van der Gaast, A, 1991)
"The combination of ifosfamide (IFO) and epirubicin (EPI) has been found to be an effective regimen in the treatment of metastatic tumours and shows remarkable activity in heavily pretreated breast cancer patients."3.68Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours. ( Hoffmann, W; Könner, J; Migeod, F; Seeber, S; Weidmann, B, 1990)
"Thirty-seven patients with widely metastatic malignant melanoma were treated with one of three chemotherapy regimens, incorporating high-dose dacarbazine (DTIC)."3.67High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. ( Carr, T; Chadwick, G; Craig, P; Jones, R; Lind, M; Morgenstern, G; Thatcher, D, 1989)
"Ifosfamide was tested in a phase II study in 12 evaluable patients with advanced malignant melanoma."3.67Phase II study with ifosfamide in advanced malignant melanoma. ( Bajetta, E; Bonfante, V; Ferrari, L; Negretti, E, 1988)
"Fifty-three patients with inoperable non-small cell bronchial carcinoma were treated at four-weekly intervals with two cytostatic drugs, doxorubicin (50 mg/m2 on day 1) and ifosfamide (2000 mg/m2 on days 1-3)."3.66[Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide]. ( Göbel, D; Matthiessen, W; Stempinski, E; Thalmann, U, 1983)
"" The regimen included an intensification of ifosfamide dosing from 1,800 mg/m(2) /day × 5 days per cycle to 2,800 mg/m(2) /day × 5 days per cycle."2.80Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma. ( Chou, AJ; Goodbody, CM; Magnan, H; Pratilas, CA; Riedel, E; Wexler, LH, 2015)
" Pharmacokinetic analysis revealed a linear relation between the area under the concentration-versus-time curve (AUC) and dose."2.75Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors. ( Akashi, Y; Fukuoka, M; Miyazaki, M; Nakagawa, K; Okamoto, I; Ozaki, T; Satoh, T; Shimizu, T; Tamura, K, 2010)
"Prognosis of patients with metastatic soft tissue sarcoma remains poor."2.75Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas: prospective, single-institutional phase II study. ( Dietrich, S; Egerer, G; Ho, AD; Kasper, B; Scharrenbroich, I; Schmitt, T; Wuchter, P, 2010)
"Grade 3/4 neutropenia was observed in 21 % of patients and grade 3/4 febrile neutropenia was seen in only one patient."2.73Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. ( Ahn, JS; Ahn, MJ; Hwang, IG; Im, YH; Kang, WK; Lee, SC; Lim, HY; Park, BB; Park, K, 2008)
"Twelve patients in stage IIIB cervical cancer were submitted to NAC and 12 (control group)--received standart pelvic radiation to whole pelvis--52 Gy."2.71[Effect of neoadjuvant chemotherapy in the treatment of patients with stage IIIB cervical cancer]. ( Gorchev, G; Kornovski, Ia, 2003)
"Ifosfamide was administered intravenously at the dose of 1,200 mg/m2 from day 1 to day 5 with uroprotection of Mesna in fusion at 0, 3, and 6 hours following initiation of IFO."2.70[Preliminary results of ifosfamide and doxorubicin regimen in treatment of patients with recurrent and metastatic nasopharyngeal carcinoma]. ( Guan, ZZ; He, YJ; Huang, HQ; Jiang, WQ; Li, YH; Teng, XY; Zhou, ZM, 2002)
"Gemcitabine was administered at a dose of 800 mg/m2 on days 1 and 8 and ifosfamide at a dose of 2 g/m2 on days 1 and 8 with adequate amount of Mesna."2.70Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. ( Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Kalofonos, H; Kiamouris, C; Nicolaides, C; Pectasides, D; Visvikis, A; Xiros, N, 2001)
"Two hundred one patients had no metastases."2.69Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. ( Cotterill, S; Craft, A; Grimer, R; Imeson, J; Lewis, I; Malcolm, A; Souhami, R; Spooner, D, 1998)
" Ifosfamide with G-CSF in combination with doxorubicin or paclitaxel achieves effective mobilization of PBPC and anti-tumor activity with minimal toxicity."2.69Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer. ( Brettell, M; Briggs, P; Chapple, P; Francis, P; Gardyn, J; Gates, P; Januszewicz, EH; Juneja, S; Millward, MJ; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Toner, GC; Wolf, M, 1999)
"Twenty-five patients with metastatic breast cancer were treated with ICE after failure of previous chemotherapy."2.69Ifosfamide, carboplatin and etoposide (ICE) in metastatic and refractory breast cancer. ( Asbury, R; Boros, L; Chang, AY; Garrow, G; Hui, L; Rubins, J, 1999)
"Consolidation of remissions of pPNET metastatic to bone and bone marrow remains a therapeutic challenge."2.68Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. ( Aledo, A; Boland, P; Casper, ES; Gerald, WL; Healey, JH; Heller, G; Kushner, BH; La Quaglia, MP; Meyers, PA; Wollner, N, 1995)
"Of 21 patients with testicular tumors who could be evaluated, 10 (47%) achieved a CR."2.68High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. ( André, T; Bonnak, H; Bouleuc, C; Donsimoni, R; Esteso, A; Firmin, C; Gerota, J; Izrael, V; Lotz, JP; Merad, Z, 1995)
"Patients with metastatic breast cancer refractory to all standard dose therapy were treated with escalating doses of mitoxantrone (45 to 105 mg/m2) and thiotepa (900 to 1,350 mg/m2) followed by autologous stem cell rescue."2.67Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities. ( Ballester, OF; Elfenbein, GJ; Fields, KK; Foody, MC; Hiemenz, JW; Janssen, WE; Kronish, LE; Perkins, JB; Zorsky, PE, 1993)
"Localized soft tissue sarcoma may be cured with complete tumor excision, but overall, outcomes are sub-optimal."2.58Selection of Patients With Localized Extremity Soft Tissue Sarcoma for Treatment With Perioperative Chemotherapy. ( Charlson, J, 2018)
"Proximal epithelioid sarcoma (PES) originating from the pleura is a clinical entity rarely reported in the literature."2.53[Pleural epithelioid sarcoma: about a case and review of the literature]. ( Akasbi, Y; Amara, B; Arifi, S; Chatar, A; Fatemi, H; Lemrabet, FZ; Mellas, N; Ouahbi, H; Oualla, K; Tizniti, S, 2016)
"Osteosarcoma is a rare tumor and any effort should be made to improve the level of International collaboration."2.52An update on chemotherapy for osteosarcoma. ( Ferrari, S; Serra, M, 2015)
"Concerning penis cancer, the optimal protocols validated by a high level of evidence are missing."2.49[Chemotherapy in male external genital organs (testicular and penile cancer)]. ( Bastide, C; Bruyère, F; Deville, JL; Flechon, A; Guy, L; Karsenty, G, 2013)
"Cervical cancer is one of the most common cancers in women."2.42[The guidelines for diagnostics and treatment of cervical cancer]. ( Inciūra, A; Juozaityte, E, 2004)
"Doxorubicin, the most active agent for breast cancer, was studied first."2.39Paclitaxel combination therapy in the treatment of metastatic breast cancer. ( Holmes, FA, 1996)
"Metastases from cystosarcoma phyllodes are rare, and treatment generally is ineffective."2.38Ifosfamide is an active drug for chemotherapy of metastatic cystosarcoma phyllodes. ( Fisher, C; Hawkins, RE; McKinna, JA; Schofield, JB; Wiltshaw, E, 1992)
"Prognosis of metastatic malignant peripheral nerve sheath tumor (MPNST) is poor and the role of chemotherapy is controversial."1.56Metastatic Malignant Peripheral Nerve Sheath Tumor With NF1 Successfully Treated With 'Gradual Subtraction' ICE Chemotherapy. ( Kakuda, Y; Katagiri, H; Miyagi, M; Murata, H; Takahashi, M; Wang, Y; Wasa, J, 2020)
"Soft tissue sarcomas are a group of tumors derived from the mesenchymal origin."1.56Epithelioid Hyalinizing Sarcoma With MGA-NUTM1 Fusion. ( Al-Rohil, RN; Bentley, RC; Cardona, DM; Feng, X; Jour, G; Shen, G; Underwood, CIM, 2020)
"On multivariate analysis, metastasectomy and objective response or stable disease achieved with first-line chemotherapy were indicators for better overall survival."1.51Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center. ( Cornillie, J; Debiec-Rychter, M; Hompes, D; Langmans, C; Schöffski, P; Sciot, R; van Cann, T; Vandenbempt, I; Wozniak, A, 2019)
"Ameloblastoma is generally characterized as a benign tumor originating in odontogenic epithelium."1.51MAID chemotherapy regimen as a treatment strategy for metastatic malignant ameloblastoma: A case report. ( Li, D; Liu, Y; Qiao, L; Sun, M; Wang, L; Xu, S, 2019)
"Multivariate analysis identified LN metastases (HR 6."1.39Factors influencing survival in metastatic synovial sarcoma: importance of patterns of metastases and the first-line chemotherapy regimen. ( Abu Sheikha, A; Al Mousa, A; Salah, S; Salem, A; Sultan, I; Yaser, S, 2013)
"Patients with infratentorial brain metastases of highly malignant pediatric non-epithelial tumors are in a severe clinical state, but still can have longer and useful lives with aggressive multimodal treatments combined with radical surgical resection."1.37Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports. ( Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M, 2011)
" No significant dose-response relationship was found in terms of LRC."1.37Sequential or concomitant chemotherapy in limited stage small-cell lung cancer. ( Anchisi, S; Bieri, S; Elhfidh, M; Khanfir, K; Matzinger, O; Mirimanoff, RO; Ozsahin, M; Zouhair, A, 2011)
"Ifosfamide is an alkylating agent with well-demonstrated efficacy against STS, and dose-dependent activity."1.37High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients. ( Baek, KK; Chang, MH; Han, B; Lee, J; Lee, SH; Lim, T; Park, JO, 2011)
"Recurrent or metastatic cervical cancer represents an aggressive malignancy with a high rate of locoregional and distant failure."1.35Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer. ( Akrivos, T; Daladimos, T; Kalinoglou, N; Karabelis, A; Karvounis, N; Kosmas, C; Malamos, N; Mylonakis, N; Tsakonas, G; Tsavaris, N; Vorgias, G, 2009)
"A 30-year-old man was diagnosed with testicular cancer, and underwent a radical orchiectomy."1.35[A case of recurrent metastatic testicular cancer, successfully treated with paclitaxel, ifomide and cisplatin]. ( Egawa, S; Hatano, T; Ito, H; Kishimoto, K; Tomita, M; Wada, T; Yanada, S, 2008)
"Fungal, viral, and nosocomial infections were uncommon."1.35Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors. ( Bosl, GJ; Feldman, DR; Ishill, N; Jathavedam, A; Motzer, RJ; Patil, S; Turkula, S; Weinstock, DM, 2008)
"Alveolar soft part sarcoma is a rare malignant tumor with unusual clinical behavior."1.33Alveolar soft part sarcoma: a rare and enigmatic entity. ( Anderson, ME; Gebhardt, MC; Hornicek, FJ; Mankin, HJ; Raskin, KA, 2005)
"Synovial sarcoma is an extremely rare primary pulmonary tumor whose description is based on a limited number of cases."1.32[Primary pulmonary synovial sarcoma: a report and diagnosis of 2 cases]. ( Baldo Padró, X; Bernadó Turmo, L; Haro Estarriol, M; Rubio Goday, M; Sebastián Quetglas, F; Viñas Villaró, G, 2003)
"The number of metastases at diagnosis and the completeness of surgical resection of all clinically detected tumor sites are of independent prognostic value in patients with proven primary metastatic osteosarcoma."1.32Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. ( Bielack, SS; Branscheid, D; Flege, S; Gadner, H; Jundt, G; Jürgens, H; Kabisch, H; Kager, L; Kastner, U; Kempf-Bielack, B; Kotz, R; Pötschger, U; Reichardt, P; Salzer-Kuntschik, M; Winkelmann, W; Zoubek, A, 2003)
"Thirty-seven patients had distant metastases at presentation."1.32Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group. ( Hatano, H; Hotta, T; Kawashima, H; Morita, T; Ogose, A; Ueda, T; Yazawa, Y, 2003)
" The bioavailability is nearly 100% after oral application, and the main metabolites are 4-hydroxytrofosfamide, and 4-hydroxyifosfamide."1.32Hypersensitivity pneumonitis associated with the use of trofosfamide. ( Hartmann, JT; Kanz, L; Kopp, HG, 2004)
"Twenty-six patients with breast cancer who had relapsed after previously receiving high-dose chemotherapy and autologous hematopoietic cell support received a second course of high-dose cytoreductive therapy and autologous hematopoietic cell support as salvage therapy."1.30High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy. ( Bearman, S; Cagnoni, P; Jones, R; Nieto, Y; Peters, W; Ross, M; Shpall, E; Vredenburgh, J, 1999)
"Patients with metastatic breast cancer will receive 4-5 cycles of induction chemotherapy on one of the ongoing Medicine Branch protocols."1.29Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. ( Chiang, Y; Cowan, KH; Dunbar, CE; Goldspiel, B; Kohler, D; McDonagh, KT; Nienhuis, AW; O'Shaughnessy, JA; Sorrentino, BP; Wilson, W, 1994)
"Twelve patients with localized Ewing's sarcoma were treated between 1980-1990 at the Istanbul School of Medicine, Department of Pediatric Oncology-Hematology, Oncology Research and Treatment Center and Our Children Leukemia Foundation."1.28Ewing's sarcoma: experience with 12 cases. ( Gedikoğlu, G; Zülfikar, B, 1992)
"Cerebral metastases occurred in 20% of all patients and was the apparent sole site of relapse in 11% of the CR patients."1.28Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy. ( Burt, P; Prendiville, J; Radford, J; Ranson, M; Steward, W; Stout, R; Thatcher, N, 1991)
"Between 1982 and 1986, 38 patients with soft tissue sarcomas were treated with a combination of ADM/DTIC (group A), another 45 (group B) received ADM/IFO between 1986 and 1990."1.28Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide. ( Dietel, M; Hossfeld, DK; Schwarz, R; Weh, HJ; Wingberg, D; Zornig, C; Zügel, M, 1990)
"All patients had histologically proven renal cell carcinoma with widespread metastases."1.27[Chemotherapy of metastatic renal cell carcinoma with cis-diamminedichloroplatinum and other drugs]. ( Akimoto, M; Hara, M; Hasegawa, J; Hirasawa, S; Kanamori, S; Kawamura, N; Nishimura, T; Ohhara, M; Okumura, S; Yoshida, K, 1984)
"Ifosfamide (Z 4942) is an alkylating agent with the structure of a cyclophosphamide analog."1.27[Treatment of pain caused by metastases of reactivated prostatic cancer with ifosfamide]. ( Kawai, T; Kihara, K; Sakuramoto, T; Satomi, Y; Takeda, T, 1983)
" Analysis of the results according to sex, age, dosage of ifosfamide and degree of histological differentiation of the tumour cells failed to show any influence of these factors on the therapeutic results."1.27Treatment of advanced malignancies with ifosfamide under protection with mesna. ( Brock, N; Guan, ZZ; He, YJ; Li, GC; Li, JQ, 1988)
"Ifosfamide (Holoxan) has an effect as a single drug on testicular carcinoma and shows synergism with cisplatinum in mice."1.26The value of ifosfamide in the polychemotherapy of metastasized testicular cancer pretreated with chemotherapy. ( Clemm, C; Hartenstein, R; Wilmanns, W, 1982)
"153 patients with inoperable malignant tumors were treated by the so-called synchronization therapy with vincristine and ifosfamide."1.26[Clinical experiences with holoxan within the framework of sequential combination therapy (author's transl)]. ( Hartwich, G; Lutz, H; Neidhardt, B, 1978)
"12 patients with extensive metastases of malignant testicular tumors and 5 other patients with other rapidly growing metastasizing tumors were treated."1.25[Cytostatic therapy of tumors under conditions of partial synchronisation with particular reference to malignant tumors of the testicle (author's transl)]. ( Jonas, U; Körner, F; Lund, S, 1975)

Research

Studies (176)

TimeframeStudies, this research(%)All Research%
pre-199021 (11.93)18.7374
1990's51 (28.98)18.2507
2000's59 (33.52)29.6817
2010's42 (23.86)24.3611
2020's3 (1.70)2.80

Authors

AuthorsStudies
Wang, Y1
Katagiri, H1
Murata, H1
Wasa, J1
Miyagi, M1
Kakuda, Y1
Takahashi, M1
Underwood, CIM1
Cardona, DM1
Bentley, RC1
Shen, G1
Feng, X1
Jour, G1
Al-Rohil, RN1
Chen, L1
Chen, Q1
Wu, Y1
Zhu, M1
Hu, J1
Zhuang, Z1
Chi, EA1
Schweizer, MT1
Wang, SY1
Xie, L1
Liu, ET1
Liao, JQ1
Chen, G1
Wang, SX1
Charlson, J1
Langmans, C1
Cornillie, J1
van Cann, T1
Wozniak, A1
Hompes, D1
Sciot, R1
Debiec-Rychter, M1
Vandenbempt, I1
Schöffski, P1
Li, D1
Xu, S1
Sun, M1
Qiao, L1
Wang, L1
Liu, Y1
Salah, S1
Yaser, S1
Salem, A1
Al Mousa, A1
Abu Sheikha, A1
Sultan, I1
Ozdemir, O1
Ozdemir, P1
Veral, A1
Uluer, H1
Ozhan, MH1
Deville, JL1
Flechon, A2
Bruyère, F1
Karsenty, G1
Guy, L1
Bastide, C1
Boye, K1
Del Prever, AB1
Eriksson, M2
Saeter, G1
Tienghi, A2
Lindholm, P2
Fagioli, F2
Skjeldal, S1
Ferrari, S5
Hall, KS2
Okuno, S1
Petersen, I1
Shives, T1
Mahoney, M1
Haddock, M1
Sim, F1
O'Connor, MI1
Markovic, SN1
Maples, W1
Kurobe, M1
Kawai, K1
Oikawa, T1
Ichioka, D1
Kandori, S1
Takaoka, E1
Kojima, T1
Joraku, A1
Suetomi, T1
Miyazaki, J1
Nishiyama, H1
Kakutani, S1
Fukuhara, H1
Taguchi, S1
Nagata, M1
Niimi, A1
Hattori, M1
Miyazaki, H2
Fujimura, T1
Nakagawa, T1
Kume, H1
Igawa, Y1
Homma, Y1
Fizazi, K1
Pagliaro, L2
Laplanche, A1
Mardiak, J1
Geoffrois, L1
Kerbrat, P1
Chevreau, C2
Delva, R1
Rolland, F2
Theodore, C1
Roubaud, G1
Gravis, G1
Eymard, JC1
Malhaire, JP1
Linassier, C1
Habibian, M1
Martin, AL1
Journeau, F1
Reckova, M1
Logothetis, C1
Culine, S1
Choeyprasert, W1
Pakakasama, S1
Sirachainan, N1
Songdej, D1
Chuansumrit, A1
Anurathapan, U1
Hongeng, S1
Nartthanarung, A1
Hadoux, J1
Rey, A2
Duvillard, P1
Lhommé, C1
Balleyguier, C1
Haie-Meder, C1
Morice, P1
Tazi, Y1
Leary, A1
Larue, C1
Pautier, P1
Magnan, H1
Goodbody, CM1
Riedel, E1
Pratilas, CA1
Wexler, LH1
Chou, AJ1
Saste, A1
Cabrera Fernandez, DF1
Gulati, R1
Gamalski, S1
Nieto, Y2
Tu, SM1
Bassett, R1
Jones, RB1
Gulbis, AM1
Tannir, N1
Kingham, A1
Ledesma, C1
Margolin, K1
Holmberg, L1
Champlin, R1
Noujaim, J1
Thway, K1
Jones, RL1
Miah, A1
Khabra, K1
Langer, R1
Kasper, B3
Judson, I2
Benson, C1
Kollàr, A1
Serra, M2
Stubbe, F1
Agaimy, A1
Ott, O1
Lettmaier, S1
Vassos, N1
Croner, R1
Hohenberger, W1
Fietkau, R1
Semrau, S1
O'Kane, G1
Bracken-Clarke, D1
Gardiner, N1
Lee, G1
Ni Chonghaile, M1
Power, D1
Daly, PA1
McCaffrey, J1
Bacon, CL1
Conneally, E1
Flynn, C1
Vandenberghe, E1
Kennedy, MJ1
Browne, PV1
O'Donnell, DM1
Hayden, PJ1
Seddon, B1
Hattinger, CM1
Biason, P1
Iacoboni, E1
Gagno, S1
Fanelli, M1
Tavanti, E1
Vella, S1
Roli, A1
Roncato, R1
Giodini, L1
Scotlandi, K1
Picci, P2
Toffoli, G1
Ouahbi, H1
Akasbi, Y1
Oualla, K1
Amara, B1
Chatar, A1
Tizniti, S1
Fatemi, H1
Lemrabet, FZ1
Arifi, S1
Mellas, N1
Gilman, AL1
Oesterheld, J1
Kollmannsberger, C3
Bokemeyer, C5
Fayette, J1
Penel, N1
Blay, JY1
Cupissol, D1
Thyss, A1
Guillemet, C1
Rios, M1
Fargeot, P1
Bay, JO1
Mathoulin-Pelissier, S1
Coindre, JM1
Bui-Nguyen, B1
DuBois, SG1
Grier, HE3
Mountzios, G1
Dimopoulos, MA4
Bamias, A1
Vourli, G1
Kalofonos, H2
Aravantinos, G3
Fountzilas, G1
Papadimitriou, CA2
Shimizu, T1
Okamoto, I1
Tamura, K1
Satoh, T1
Miyazaki, M1
Akashi, Y1
Ozaki, T1
Fukuoka, M1
Nakagawa, K1
Briccoli, A2
Rocca, M2
Salone, M1
Palmerini, E1
Balladelli, A1
Ferrari, C1
Di Fiore, M1
Bacci, G2
Stroppa, E1
Bertuzzi, A1
Di Comite, G1
Mussi, C1
Lutman, RF1
Barbato, A1
Santoro, A1
Kosmas, C3
Mylonakis, N2
Tsakonas, G2
Vorgias, G1
Karvounis, N1
Tsavaris, N2
Daladimos, T1
Kalinoglou, N1
Malamos, N2
Akrivos, T1
Karabelis, A2
Scharrenbroich, I1
Schmitt, T2
Wuchter, P1
Dietrich, S1
Ho, AD1
Egerer, G2
Moon, YW1
Sohn, JH1
Choi, HJ1
Chang, H1
Park, BW1
Kim, SI1
Park, S1
Koo, JS1
Kim, YT1
Roh, JK1
Chung, HC1
Kim, JH1
Dimitrakopoulou-Strauss, A1
Strauss, LG1
Vasamiliette, J1
Haberkorn, U1
Staudacher, L1
Cottu, PH1
Diéras, V1
Vincent-Salomon, A1
Guilhaume, MN1
Escalup, L1
Dorval, T1
Beuzeboc, P1
Mignot, L1
Pierga, JY1
Daugaard, G1
Skoneczna, I1
Aass, N1
De Wit, R1
De Santis, M1
Dumez, H1
Marreaud, S2
Collette, L1
Lluch, JRG1
Schmoll, HJ4
Osawa, S1
Kumabe, T1
Saito, R1
Sonoda, Y1
Niizuma, H1
Watanabe, M1
Tominaga, T1
Mora, J1
de Torres, C1
Parareda, A1
Torner, F1
Galván, P1
Rodríguez, E1
Cardesa, T1
Salvador, H1
Suñol, M1
Huguet, R1
Cruz, O1
Collins, IM1
Thomas, DM1
Khanfir, K1
Elhfidh, M1
Anchisi, S1
Matzinger, O1
Bieri, S1
Mirimanoff, RO1
Ozsahin, M1
Zouhair, A1
Lee, SH1
Chang, MH1
Baek, KK1
Han, B1
Lim, T1
Lee, J1
Park, JO1
Ray-Coquard, I1
Luksch, R1
Barbieri, E1
Gandola, L1
Ruggieri, P1
Daolio, P1
Prete, A1
Bisogno, G2
Tamburini, A1
Grignani, G1
Abate, ME1
Podda, M1
Smeland, S1
Hervonen, P1
Tulijoki, T1
Kellokumpu-Lehtinen, P1
Frøen, H1
Brennhovd, B1
Abeler, VM1
Madsbu, UE1
Lehne, G1
Batschinski, K1
Dervisis, NG1
Kitchell, BE1
Hawkins, DS1
Felgenhauer, J2
Park, J1
Kreissman, S1
Thomson, B1
Douglas, J1
Rowley, SD1
Gooley, T1
Sanders, JE1
Pendergrass, TW1
Rozan, O1
Janot, F1
Oberlin, O2
Schwaab, G1
Quintana, E2
Tran Ba Huy, P1
Georges, B1
Luboinski, B1
Huang, HQ1
Zhou, ZM1
Li, YH1
Jiang, WQ1
He, YJ2
Teng, XY1
Guan, ZZ2
Souquet, PJ1
Tan, EH1
Rodrigues Pereira, J1
Van Klaveren, R1
Price, A1
Gatzemeier, U1
Jaworski, M1
Burillon, JP1
Aubert, D1
Janinis, J1
McTiernan, A1
Driver, D1
Mitchell, C1
Cassoni, AM1
Pringle, J1
Kilby, A1
Whelan, JS1
Indrová, M1
Bubeník, J1
Mikysková, R1
Mendoza, L1
Símová, J1
Bieblová, J1
Jandlová, T1
Jinoch, P1
Smahel, M1
Vonka, V1
Pajtasz-Piasecka, E1
Haro Estarriol, M1
Baldo Padró, X1
Rubio Goday, M1
Sebastián Quetglas, F1
Viñas Villaró, G1
Bernadó Turmo, L1
Kager, L1
Zoubek, A1
Pötschger, U1
Kastner, U1
Flege, S1
Kempf-Bielack, B1
Branscheid, D1
Kotz, R1
Salzer-Kuntschik, M1
Winkelmann, W1
Jundt, G2
Kabisch, H1
Reichardt, P2
Jürgens, H1
Gadner, H1
Bielack, SS1
Ogose, A1
Yazawa, Y1
Ueda, T1
Hotta, T1
Kawashima, H1
Hatano, H1
Morita, T1
Donati, D1
Longhi, A1
Bertoni, F1
Bacchini, P1
Giacomini, S1
Forni, C1
Manfrini, M1
Galletti, S1
Vrdoljak, E1
Hamm, W1
Omrcen, T1
Prskalo, T1
Gorchev, G1
Kornovski, Ia1
Inciūra, A1
Juozaityte, E1
Kopp, HG1
Kanz, L4
Hartmann, JT3
Miser, JS2
Krailo, MD1
Tarbell, NJ1
Link, MP2
Fryer, CJ1
Pritchard, DJ1
Gebhardt, MC3
Dickman, PS1
Perlman, EJ1
Meyers, PA2
Donaldson, SS2
Moore, S1
Rausen, AR1
Vietti, TJ1
Stenning, S1
Horwich, A1
Clemm, C3
Gerl, A1
Meisner, C2
Rückerl, CP1
Oliver, T1
Altundag, K1
Aksoy, S1
Gullu, I1
Altundag, O1
Ozyar, E1
Yalcin, S1
Cengiz, M1
Akyol, F1
Heymann, D1
Ory, B1
Blanchard, F1
Heymann, MF1
Coipeau, P1
Charrier, C1
Couillaud, S1
Thiery, JP1
Gouin, F1
Redini, F1
Orbach, D1
Sanchez de Toledo, J1
Terrier-Lacombe, MJ1
van Unnik, A1
Stevens, MC1
Anderson, ME1
Hornicek, FJ1
Raskin, KA1
Mankin, HJ1
Leyvraz, S2
Zweifel, M1
Lissoni, A1
Cerny, T1
Sessa, C1
Fey, M1
Dietrich, D1
Honegger, HP1
Indolfi, P1
Casale, F1
Cecchetto, G1
De Salvo, G1
Ferrari, A1
Donfrancesco, A1
Donofrio, V1
Martone, A1
Di Martino, M1
Di Tullio, MT1
Nielsen, OS1
Christensen, TB1
Pink, D1
Daugaard, S1
Hermans, C1
van Glabbeke, M1
Blay, J1
Cok, G1
Göksel, T1
Soyer, S1
Atil, H1
Güzelant, A1
Aysan, T1
Brain, EG1
Rezai, K1
Weill, S1
Gauzan, MF1
Santoni, J1
Besse, B1
Goupil, A1
Turpin, F1
Urien, S1
Lokiec, F1
Kondagunta, GV1
Bacik, J1
Sheinfeld, J1
Bajorin, D1
Bains, M1
Reich, L1
Deluca, J1
Budnick, A1
Ishill, N2
Mazumdar, M1
Bosl, GJ2
Motzer, RJ2
Lin, CC1
Hsu, CH1
Huang, CY1
Keng, HY1
Tsai, YC1
Huang, KH1
Cheng, AL1
Pu, YS1
Gassiamis, A1
Skopelitis, H1
Polyzos, A1
Piantedosi, FV1
Caputo, F1
Mazzarella, G1
Gilli, M1
Pontillo, A1
D'Agostino, D1
Campbell, S1
Marsico, SA1
Bianco, A1
Goto, T1
Okuma, T1
Nakada, I1
Hozumi, T1
Kondo, T1
Tascilar, M1
Loos, WJ1
Seynaeve, C1
Verweij, J1
Sleijfer, S1
Yanada, S1
Ito, H1
Tomita, M1
Wada, T1
Hatano, T1
Kishimoto, K1
Egawa, S1
Verma, S1
Younus, J1
Stys-Norman, D1
Haynes, AE1
Blackstein, M1
Park, BB1
Im, YH1
Hwang, IG1
Lee, SC1
Ahn, JS1
Ahn, MJ1
Lim, HY1
Kang, WK1
Park, K1
Recchia, F1
Candeloro, G1
Di Staso, M1
Necozione, S1
Bisegna, R1
Bratta, M1
Tombolini, V1
Rea, S1
Jathavedam, A1
Feldman, DR1
Turkula, S1
Patil, S1
Weinstock, DM1
Okumura, S1
Nishimura, T1
Yoshida, K1
Ohhara, M1
Hasegawa, J1
Hirasawa, S1
Hara, M1
Kawamura, N1
Kanamori, S1
Akimoto, M1
Kawai, T1
Takeda, T1
Kihara, K1
Sakuramoto, T1
Satomi, Y1
Matthiessen, W1
Stempinski, E1
Göbel, D1
Thalmann, U1
Hartenstein, R1
Wilmanns, W1
O'Shaughnessy, JA1
Cowan, KH1
Nienhuis, AW2
McDonagh, KT1
Sorrentino, BP2
Dunbar, CE2
Chiang, Y1
Wilson, W1
Goldspiel, B1
Kohler, D1
Lind, MJ1
Gumbrell, L1
Cantwell, BM1
Millward, MJ3
Simmonds, D1
Proctor, M1
Chapman, F1
McCann, E1
Middleton, I1
Calvert, AH1
Schleicher, UM1
Adam, G1
Casser, HR1
Füzesi, L1
González-Manzano, R1
Cid, J1
Brugarolas, A1
Piasecki, CC1
Kushner, BH1
Gerald, WL1
Healey, JH1
La Quaglia, MP1
Boland, P1
Wollner, N1
Casper, ES1
Aledo, A1
Heller, G1
Perkins, JB3
Fields, KK3
Elfenbein, GJ3
Lotz, JP1
André, T1
Donsimoni, R1
Firmin, C1
Bouleuc, C1
Bonnak, H1
Merad, Z1
Esteso, A1
Gerota, J1
Izrael, V1
Harris, MB2
Cantor, AB1
Goorin, AM2
Shochat, SJ1
Ayala, AG1
Ferguson, WS1
Holbrook, T1
Stewart, FM1
Quesenberry, P1
O'Shaughnessy, J1
Cowan, K1
Cottler-Fox, M1
Leitman, S1
Goodman, S1
Harstrick, A2
Illiger, HJ2
Metzner, B2
Räth, U1
Hohnloser, J1
Berdel, W1
Siegert, W1
Hiemenz, JW1
Janssen, WE1
Zorsky, PE1
Ballester, OF1
Kronish, LE1
Foody, MC1
Ingle, JN1
Krook, JE1
Mailliard, JA1
Hartmann, LC1
Wieand, HS1
Moscinski, LC1
Droz, JP1
Biron, P1
Sutton, G1
Blessing, JA1
Park, R1
DiSaia, PJ1
Rosenshein, N1
Becher, R3
Kloke, O2
Hayungs, J1
Hartwich, G2
Bartels, H1
Szanto, J1
Wolf, E1
Halabi, S1
Rieche, K1
Hering, KG1
Ohl, S1
DeDycker, R1
Huhn, R1
Fischedick, AR1
Höfeler, H2
Pielken, HJ1
Hawig, I1
Hirche, H1
Seeber, S2
Leone, BA1
Vallejo, CT1
Romero, AO1
Perez, JE1
Cuevas, MA1
Lacava, JA1
Sabatini, CL1
Dominguez, ME1
Rodriguez, R1
Barbieri, MR1
Ortiz, EH1
Salvadori, MA1
Acuña, LA1
Acuña, JM1
Langhi, MJ1
Amato, S1
Machiavelli, MR1
Holmes, FA2
Fetscher, S1
Brugger, W1
Engelhardt, R1
Hasse, J1
Frommhold, H1
Wenger, M1
Lange, W1
Mertelsmann, R1
Pronzato, P1
Queirolo, P1
Landucci, M1
Vaira, F1
Vigani, A1
Gipponi, M1
Cafiero, F1
Kyriakakis, Z1
Kostakopoulos, A1
Karayiannis, A1
Sofras, F1
Zervas, A1
Giannopoulos, A1
Dimopoulos, C1
Colucci, G1
Gebbia, V1
Galetta, D1
Riccardi, F1
Cariello, S1
Gebbia, N1
Shin, DM2
Glisson, BS2
Khuri, FR2
Ginsberg, L2
Lawhorn, K2
Hong, WK2
Lippman, SM2
Papadimitrakopoulou, V1
Lee, JJ1
Gillenwater, AM1
Ang, KK1
Clayman, GL1
Callender, DL1
Chen, YM1
Liu, JM1
Wu, MF1
Wu, HW1
Lin, WC1
Tsai, CM1
Perng, RP1
Whang-Peng, J1
Walters, RS1
Valero, V1
Esparza-Guerra, L1
Hortobagyi, GN2
Craft, A1
Cotterill, S1
Malcolm, A1
Spooner, D2
Grimer, R2
Souhami, R1
Imeson, J1
Lewis, I2
Comandone, A1
Leone, L1
Oliva, C1
Frustaci, S1
Monteleone, M1
Colussi, AM1
Dal Canton, O1
Bergnolo, P1
Boglione, A1
Bumma, C1
Huober, J1
Schneeweiss, A1
Hohaus, S1
Wittmann, G1
Meyer, A1
Martin, S1
Goldschmidt, H1
Bastert, G1
Haas, R1
Wallwiener, D1
Prince, HM2
Gardyn, J1
Rischin, D2
Francis, P2
Gates, P2
Chapple, P2
Quinn, M2
Juneja, S2
Wolf, M2
Januszewicz, EH2
Richardson, G2
Scarlett, J2
Briggs, P2
Brettell, M2
Toner, GC2
Blakey, D1
Seymour, JF1
Strickland, A1
Zalcberg, J1
Bearman, S1
Vredenburgh, J1
Cagnoni, P1
Shpall, E1
Ross, M1
Peters, W1
Jones, R2
Beyer, J1
Einhorn, L2
Nichols, C1
Perey, L1
Rosti, G1
Lange, A1
Pampallona, S1
Peters, R1
Humblet, Y1
Bosquée, L1
Pasini, F1
Marangolo, M1
Aziz, Z1
Rehman, A1
Qazi, S1
Lobo, F1
Frau, A1
Barnadas, A1
Méndez, M1
Lizón, J1
Provencio, M1
Albistur, JJ1
Martínez, P1
Sánchez, MJ1
Constenla, M1
Estévez, LG1
Chang, AY1
Hui, L1
Asbury, R1
Boros, L1
Garrow, G1
Rubins, J1
Hawkins, D1
Pendergrass, T1
Lindsley, K1
Conrad, EU1
Shankar, AG1
Pinkerton, CR1
Atra, A1
Ashley, S1
Cannon, S1
Cotterill, SJ1
Craft, AW1
Chua, DT1
Kwong, DL1
Sham, JS1
Au, GK1
Choy, D1
Edelman, MJ1
Tsavaris, NB1
Malamos, NA1
Vadiaka, M1
Koufos, C1
Thurnher, D1
Kornfehl, J1
Burian, M1
Gedlicka, C1
Selzer, E1
Quint, C1
Neuchrist, C1
Kornek, GV1
Sreerama, L1
Sládek, NE1
Horibe, K1
Fukuda, M1
Miyajima, Y1
Matsumoto, K1
Kondo, M1
Inaba, J1
Miyashita, Y1
Rixe, O1
Köstler, WJ1
Brodowicz, T1
Attems, Y1
Hejna, M1
Tomek, S1
Amann, G1
Fiebiger, WC1
Wiltschke, CH1
Krainer, M1
Zielinski, CC1
Sandler, E1
Lyden, E2
Ruymann, F1
Maurer, H1
Wharam, M2
Parham, D1
Link, M2
Crist, W1
Pectasides, D1
Kiamouris, C1
Bafaloukos, D2
Xiros, N1
Nicolaides, C1
Visvikis, A1
Bernstein, M1
Ferguson, W1
Devidas, M1
Siegal, GP1
Schwartz, CL1
Breitfeld, PP1
Raney, RB1
Teot, LA1
Lobe, T1
Crist, WM1
Maurer, HM1
Ruymann, FB1
von der Maase, H1
Seo, JH1
Whang, YM1
Kim, BS1
Choi, CW1
Shin, SW1
Kim, YH1
Kim, JS1
Goo, BH1
Sarris, K1
Kalofonos, C1
Gika, D1
Gourgoulis, GM1
Efstathiou, E1
Skarlos, D1
Körner, F2
Lund, S1
Jonas, U1
Buzdar, AU1
Legha, SS1
Tashima, CK1
Yap, HY1
Hersh, EM1
Blumenschein, GR1
Bodey, GP1
Schmidt, CG2
Kokron, O3
Titscher, R2
Micksche, M1
Cerni, C1
Wrba, H1
Neidhardt, B1
Lutz, H1
Corsi, A1
Calabresi, F1
Greco, C1
Wicart, L1
Loehrer, PJ1
Rynard, S1
Ansari, R1
Songer, J1
Pennington, K1
Hawkins, RE1
Schofield, JB1
Wiltshaw, E2
Fisher, C1
McKinna, JA1
Hirano, M1
Okamoto, M1
Maruyama, F1
Ezaki, K1
Shimizu, K1
Ino, T1
Matsui, T1
Sobue, R1
Shinkai, K1
Zülfikar, B1
Gedikoğlu, G1
Gurney, H1
de Campos, ES1
Dodwell, D1
Kamthan, A1
Thatcher, N2
Prendiville, J1
Radford, J1
Steward, W1
Ranson, M1
Burt, P1
Stout, R1
Lange, OF1
Scheef, W2
Haase, KD1
Heckmann, M1
Leyendecker, R1
Urban, G1
Zegners, G1
Kok, TC1
van der Gaast, A1
Splinter, TA1
Tilanus, HW1
Weh, HJ1
Zügel, M1
Wingberg, D1
Schwarz, R1
Zornig, C1
Dietel, M1
Hossfeld, DK1
Meier, W1
Eiermann, W1
Stieber, P1
Fateh-Moghadam, A1
Schneider, A1
Hepp, H1
Coleman, RE1
Clarke, JM1
Slevin, ML1
Sweetenham, J1
Williams, CJ1
Blake, P1
Calman, F1
Harper, PG1
Ghavamzadeh, A1
Hoffmann, W1
Weidmann, B1
Migeod, F1
Könner, J1
Kaye, SB1
Stoter, G1
Sleijfer, D1
Jones, W1
Ten Bokkel Huinink, W1
Splinter, T1
Van Oosterom, A1
Harris, A1
Boven, E1
De Pauw, M1
Kurschel, E1
Schilcher, RB1
Weinhardt, O1
Wandl, U1
Thatcher, D1
Lind, M1
Morgenstern, G1
Carr, T1
Chadwick, G1
Craig, P1
Li, GC1
Brock, N1
Li, JQ1
Negretti, E1
Ferrari, L1
Bonfante, V1
Bajetta, E1
Paprocka, M1
Radzikowski, C1
Einhorn, LH1
Hoefer, H1

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors[NCT00104676]Phase 3263 participants (Actual)Interventional2003-11-26Active, not recruiting
High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors[NCT00936936]Phase 264 participants (Actual)Interventional2009-06-02Active, not recruiting
A Randomized Phase III Study of Sequential High-Dose Cisplatinum/Etoposide/Ifosfamide Plus Stem Cell Support Versus BEP in Patients With Poor Prognosis Germ Cell Cancer[NCT00003941]Phase 3222 participants (Anticipated)Interventional1999-04-30Completed
Observational Study on Treatment of Skeletal Ewing Sarcoma at Diagnosis[NCT04845893]100 participants (Anticipated)Observational2021-06-01Recruiting
A Multi-Centre Phase II Study Using Carboplatin AUC-10 for Metastatic Seminoma With IGCCCG Good Prognosis Disease-Therapy Directed by Initial Metabolic Response on PET-CT[NCT02272816]Phase 248 participants (Actual)Interventional2012-02-13Completed
A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, With Cross-Over at Disease Progression[NCT01391962]Phase 234 participants (Actual)Interventional2011-07-18Active, not recruiting
Continuous 5 Days Infusion of High Dose Ifosfamide and Adriamycin in Patients With Advanced Sarcoma[NCT00002526]Phase 220 participants (Actual)Interventional1993-01-31Completed
PHASE I/II TRIAL OF SEQUENTIAL TAXOL/IFOSFAMIDE AND DOSEINTENSIVE CARBOPLATIN/ETOPOSIDE WITH STEM CELL SUPPORT IN CISPLATIN-RESISTANT GERM CELL TUMOR PATIENTS WITH UNFAVORABLE PROGNOSTIC FEATURES[NCT00002558]Phase 1/Phase 2108 participants (Actual)Interventional1994-01-31Completed
Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Ifosfamide, Followed by Resection and Radiotherapy in Patients With Peripheral Primitive Neuroectodermal Tumors or Ewing's Sarcoma[NCT00002466]Phase 20 participants Interventional1990-05-31Completed
Endometrial Stromal Tumors: an Observational Study[NCT02829437]100 participants (Anticipated)Observational2016-10-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Overall Survival

To evaluated the overall survival in both groups in participants presenting fast and slow decrease in serum levels of tumor markers. The median overall survival was defined as the median percentage of participants alive after 1 course of treatment. (NCT00104676)
Timeframe: 3 years from randomization

Interventionpercentage of participants (Number)
Arm I65
Arm II73

Progression-free Survival Rate After 1 Course of Treatment

Primary objective is to compare the progression-free survival of participants after 1 cycle of treatment, treated randomly by 3 additional cycles of BEP (Arm I) or by T-BEP-Oxaliplatin/cisplatin-ifosfamide-Bleomycin (Arm II). The median progression-free survival rate was defined as the median percentage of participants alive without disease progression after 1 course of treatment. (NCT00104676)
Timeframe: 3 years from randomization

Interventionpercentage of participants (Number)
Arm I48
Arm II59

2 - Year Progression Free Survival

Number of participants progression free 2 years after registration. (NCT02272816)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
Carboplatin AUC-1046

Overall Objective Response

Overall Objective Response will be assessed prior to dose-intensive therapy and at the completion of therapy. Complete disappearance of all clinical, radiographic and biochemical (normal AFP and HCG) evidence of disease for a minimum of 4 weeks (CR to chemotherapy). Patients must be free of disease for a minimum of 4 weeks. Partial Response: Complete disappearance of all biochemical evidence of disease in patients without a surgical procedure for a residual radiographic mass. Patients must demonstrate no biochemical recurrence or progression of radiographic masses for a minimum of four weeks (PR to chemotherapy} (NCT00002558)
Timeframe: 2 years

,
Interventionparticipants (Number)
Complete Response (CR)Incomplete Response (IR)Partial Response (PR)
Group A50365
Group B483

Reviews

14 reviews available for ifosfamide and Metastase

ArticleYear
Selection of Patients With Localized Extremity Soft Tissue Sarcoma for Treatment With Perioperative Chemotherapy.
    Current treatment options in oncology, 2018, 10-25, Volume: 19, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D

2018
[Chemotherapy in male external genital organs (testicular and penile cancer)].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2013, Volume: 23, Issue:15

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Chemotherapy, Adjuvant; Cisp

2013
An update on chemotherapy for osteosarcoma.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:18

    Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Clinical Tri

2015
First-line treatment in advanced or metastatic disease: one size fits all or adapted to specific histiotypes?
    Current opinion in oncology, 2016, Volume: 28, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials,

2016
[Pleural epithelioid sarcoma: about a case and review of the literature].
    The Pan African medical journal, 2016, Volume: 25

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fatal Outcome; Female; Humans; I

2016
Salvage chemotherapy after failure of first-line chemotherapy in patients with metastatic testicular cancer.
    Current opinion in supportive and palliative care, 2008, Volume: 2, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dose-Response R

2008
[The guidelines for diagnostics and treatment of cervical cancer].
    Medicina (Kaunas, Lithuania), 2004, Volume: 40, Issue:4

    Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic;

2004
The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.
    The oncologist, 2007, Volume: 12, Issue:11

    Topics: Adult; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Doxorubicin; Drug Thera

2007
Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma.
    Cancer treatment reviews, 2008, Volume: 34, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Humans; Ifosfam

2008
High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts.
    Annals of the New York Academy of Sciences, 1995, Dec-29, Volume: 770

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carboplatin; Cycl

1995
Paclitaxel combination therapy in the treatment of metastatic breast cancer.
    Seminars in oncology, 1996, Volume: 23, Issue:5 Suppl 12

    Topics: Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan

1996
New approaches to treatment of metastatic bladder cancer.
    Current oncology reports, 2000, Volume: 2, Issue:5

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe

2000
Current and future perspectives in advanced bladder cancer: is there a new standard?
    Seminars in oncology, 2002, Volume: 29, Issue:1 Suppl 3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogeni

2002
Ifosfamide is an active drug for chemotherapy of metastatic cystosarcoma phyllodes.
    Cancer, 1992, May-01, Volume: 69, Issue:9

    Topics: Adult; Breast Neoplasms; Female; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Metastasis; Phyllo

1992

Trials

78 trials available for ifosfamide and Metastase

ArticleYear
High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study.
    Pediatric blood & cancer, 2014, Volume: 61, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2014
Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation GM-CSF During Preoperative Irradiation and Postoperatively.
    American journal of clinical oncology, 2016, Volume: 39, Issue:2

    Topics: Administration, Inhalation; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

2016
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:13

    Topics: Adolescent; Adult; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomark

2014
Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:22

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chemotherap

2014
Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Disease-Free Survival;

2015
Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.
    Investigational new drugs, 2009, Volume: 27, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship

2009
Chemotherapy: The role of ifosfamide and etoposide in Ewing sarcoma.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dactinomycin; Disease-Free Surviva

2009
Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule

2009
Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:2

    Topics: Aged; Antineoplastic Agents; Female; Glucose; Humans; Ifosfamide; Infusions, Intravenous; Male; Midd

2010
Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas.
    Investigational new drugs, 2010, Volume: 28, Issue:6

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; H

2010
Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas: prospective, single-institutional phase II study.
    Bone marrow transplantation, 2010, Volume: 45, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxorubicin; Hemat

2010
Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis.
    European journal of nuclear medicine and molecular imaging, 2010, Volume: 37, Issue:8

    Topics: Discriminant Analysis; Doxorubicin; Drug Therapy, Combination; Fluorodeoxyglucose F18; Follow-Up Stu

2010
A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EO
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:5

    Topics: Adolescent; Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T

2011
Treatment of Ewing sarcoma family of tumors with a modified P6 protocol in children and adolescents.
    Pediatric blood & cancer, 2011, Jul-15, Volume: 57, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid

2011
No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer.
    Anticancer research, 2012, Volume: 32, Issue:8

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Ifosfami

2012
[Preliminary results of ifosfamide and doxorubicin regimen in treatment of patients with recurrent and metastatic nasopharyngeal carcinoma].
    Ai zheng = Aizheng = Chinese journal of cancer, 2002, Volume: 21, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Ifosfamide; Male

2002
GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L

2002
Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arm; Bone Neoplasms; Child; Child

2003
[Effect of neoadjuvant chemotherapy in the treatment of patients with stage IIIB cervical cancer].
    Akusherstvo i ginekologiia, 2003, Volume: 42, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemothe

2003
Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-15, Volume: 22, Issue:14

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2004
Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials.
    British journal of cancer, 2004, Aug-16, Volume: 91, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carb

2004
Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jul-01, Volume: 23, Issue:19

    Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphami

2005
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxorubicin; Femal

2006
Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:14

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship,

2006
Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study.
    Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:3

    Topics: Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Cross-Over Studies; Drug Administration

2007
Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jan-01, Volume: 25, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Surviva

2007
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study.
    Anti-cancer drugs, 2007, Volume: 18, Issue:4

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An

2007
Docetaxel-ifosfamide combination in patients with advanced breast cancer failing prior anthracycline-based regimens: results of a phase I-II study.
    Journal of chemotherapy (Florence, Italy), 2007, Volume: 19, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Respo

2007
Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycy

2008
Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma.
    Investigational new drugs, 2008, Volume: 26, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di

2008
Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2008, Volume: 31, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; CD4-CD8 Ratio

2008
The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer.
    British journal of cancer, 1995, Volume: 71, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedul

1995
Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study.
    British journal of cancer, 1995, Volume: 72, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa

1995
Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr

1995
Ifosfamide/carboplatin/etoposide chemotherapy for metastatic breast cancer with or without autologous hematopoietic stem cell transplantation: evaluation of dose-response relationships.
    Seminars in oncology, 1995, Volume: 22, Issue:3 Suppl 7

    Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbo

1995
High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.
    Cancer, 1995, Feb-01, Volume: 75, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carb

1995
Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study.
    Medical and pediatric oncology, 1995, Volume: 24, Issue:2

    Topics: Adolescent; Adult; Child; Clinical Trials, Phase II as Topic; Female; Humans; Ifosfamide; Male; Neop

1995
A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:16

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Germinoma; Granulocyte-Macroph

1993
Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities.
    Seminars in oncology, 1993, Volume: 20, Issue:5 Suppl 6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms

1993
Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer.
    American journal of clinical oncology, 1995, Volume: 18, Issue:6

    Topics: Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cystitis; Drug Administration Schedule; D

1995
Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group.
    Obstetrics and gynecology, 1996, Volume: 87, Issue:5 Pt 1

    Topics: Antineoplastic Agents, Alkylating; Drug Administration Schedule; Endometrial Neoplasms; Female; Huma

1996
Epirubicin and ifosfamide in metastatic breast cancer.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin;

1996
Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Ifosf

1996
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carc

1997
Phase II study of vinorelbine and ifosfamide in anthracycline resistant metastatic breast cancer.
    Breast cancer research and treatment, 1997, Volume: 42, Issue:2

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo

1997
Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer.
    The Journal of urology, 1997, Volume: 158, Issue:2

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic A

1997
Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
    British journal of cancer, 1997, Volume: 76, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat

1997
Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr

1997
Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carc

1998
Ifosfamide-based chemotherapy for previously treated lung cancer patients.
    Zhonghua yi xue za zhi = Chinese medical journal; Free China ed, 1998, Volume: 61, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcino

1998
Phase II study of ifosfamide and mesna in patients with metastatic breast cancer.
    American journal of clinical oncology, 1998, Volume: 21, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Female; Humans; Ifosfamide; Mesna;

1998
Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

1998
Tandem and triple high-dose chemotherapy with autologous stem cell rescue in metastatic breast cancer.
    Journal of cancer research and clinical oncology, 1998, Volume: 124, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Epirubicin; Fe

1998
Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer.
    Bone marrow transplantation, 1999, Volume: 23, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Combined

1999
Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Combined Modalit

1999
Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Dose-

1999
Ifosfamide and vinorelbine in metastatic breast cancer in patients with prior anthracycline therapy.
    Cancer chemotherapy and pharmacology, 1999, Volume: 44 Suppl

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asthenia;

1999
Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy.
    Cancer chemotherapy and pharmacology, 1999, Volume: 44 Suppl

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo

1999
Ifosfamide, carboplatin and etoposide (ICE) in metastatic and refractory breast cancer.
    Cancer chemotherapy and pharmacology, 1999, Volume: 44 Suppl

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Drug Res

1999
Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas.
    Medical and pediatric oncology, 2000, Volume: 34, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Child; Child, Preschool; Cyc

2000
A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy.
    European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Follow-Up Studies; Huma

2000
Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jan-01, Volume: 19, Issue:1

    Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell

2001
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Anti-cancer drugs, 2001, Volume: 12, Issue:3

    Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

2001
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:9

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Disease Pro

2001
Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group.
    Medical and pediatric oncology, 2001, Volume: 37, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Doxorubi

2001
Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:10

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; He

2001
Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jan-15, Volume: 20, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Disease-Fr

2002
Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
    Journal of pediatric hematology/oncology, 2001, Volume: 23, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bronchiolit

2001
A Phase II study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma.
    Cancer, 2002, Apr-01, Volume: 94, Issue:7

    Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Pro

2002
Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group.
    Gynecologic oncology, 2002, Volume: 85, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Ad

2002
Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer.
    Cancer treatment reports, 1979, Volume: 63, Issue:1

    Topics: Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination

1979
[Clinical experiences with Holoxan in small cell carcinoma of the bronchus (author's transl)].
    Osterreichische Zeitschrift fur Onkologie. Austrian journal of oncology, 1977, Nov-15, Volume: 4, Issue:5-6

    Topics: Bronchial Neoplasms; Carcinoma; Cyclophosphamide; Humans; Ifosfamide; Male; Neoplasm Metastasis; Qua

1977
[Ifosfamide in the treatment of solid tumors and their metastases].
    La Nouvelle presse medicale, 1976, Apr-10, Volume: 5, Issue:15

    Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Tolerance; Female; Humans;

1976
Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer.
    Cancer, 1992, Feb-01, Volume: 69, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female;

1992
Palliative chemo-radiotherapy with ifosfamide and epirubicin as first-line treatment for high-risk metastatic breast cancer. Results of a prospective multicenter trial.
    Cancer chemotherapy and pharmacology, 1990, Volume: 26 Suppl

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The

1990
Potential advances in combination chemotherapy for advanced testicular cancer.
    Progress in clinical and biological research, 1988, Volume: 269

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials as Topic; Etop

1988
[Treatment of oat cell metastazing bronchial carcinoma with isofosfamide. Results of a prospective randomized study].
    Osterreichische Zeitschrift fur Onkologie. Austrian journal of oncology, 1974, Issue:5-6

    Topics: Aged; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Humans; If

1974
[Treatment of bronchogenic cancer and lung metastases of solid tumors with ifosfamid (author's transl)].
    Osterreichische Zeitschrift fur Onkologie. Austrian journal of oncology, 1974, Issue:1

    Topics: Carcinoma, Bronchogenic; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Female; Humans

1974

Other Studies

84 other studies available for ifosfamide and Metastase

ArticleYear
Metastatic Malignant Peripheral Nerve Sheath Tumor With NF1 Successfully Treated With 'Gradual Subtraction' ICE Chemotherapy.
    Anticancer research, 2020, Volume: 40, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; M

2020
Epithelioid Hyalinizing Sarcoma With MGA-NUTM1 Fusion.
    American journal of clinical pathology, 2020, 11-04, Volume: 154, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Transcription Factors; Cyclop

2020
MTSS1 inhibits colorectal cancer metastasis by regulating the CXCR4/CXCL12 signaling axis.
    International journal of molecular medicine, 2021, Volume: 47, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Chemokine CXCL12; Cisplatin; Colorectal Neo

2021
Durable Response to Immune Checkpoint Blockade in a Platinum-Refractory Patient With Nonseminomatous Germ Cell Tumor.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:5

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Ifosfamid

2017
FDG-PET/CT of invasive thymoma extending into the superior vena cava and right atrium.
    Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2019, Volume: 26, Issue:5

    Topics: Aged; Cisplatin; Fluorodeoxyglucose F18; Heart Atria; Humans; Ifosfamide; Male; Neoplasm Metastasis;

2019
Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center.
    Oncology research and treatment, 2019, Volume: 42, Issue:7-8

    Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Doxorubicin; Female; Humans; Ifosfamide; Li

2019
MAID chemotherapy regimen as a treatment strategy for metastatic malignant ameloblastoma: A case report.
    Medicine, 2019, Volume: 98, Issue:25

    Topics: Adult; Ameloblastoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine;

2019
Factors influencing survival in metastatic synovial sarcoma: importance of patterns of metastases and the first-line chemotherapy regimen.
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Disease-Free Survival; Dox

2013
ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carb

2013
Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor.
    Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Consolidation Chemotherapy; Drug R

2015
Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma.
    Japanese journal of clinical oncology, 2015, Volume: 45, Issue:3

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Doce

2015
Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015, Volume: 25, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Cisplatin; Combined Modali

2015
A trimodality approach in the management of metastatic low-grade epithelioid hemangioendothelioma of the bone.
    BMJ case reports, 2015, Jul-16, Volume: 2015

    Topics: Adult; Antineoplastic Agents; Bone Nails; Bone Neoplasms; Doxorubicin; Femur; Foot; Fracture Fixatio

2015
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; C

2015
Adult Pleomorphic Rhabdomyosarcoma: A Multicentre Retrospective Study.
    Anticancer research, 2015, Volume: 35, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposi

2015
Effective local control of advanced soft tissue sarcoma with neoadjuvant chemoradiotherapy and surgery: A single institutional experience.
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2016, Volume: 20, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Doxorubici

2016
A single-centre analysis of 30 patients with relapsed germ cell tumours treated with the TI-CE regimen.
    Bone marrow transplantation, 2016, Volume: 51, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplati

2016
Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.
    Oncotarget, 2016, Sep-20, Volume: 7, Issue:38

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms

2016
Myeloablative chemotherapy with autologous stem cell rescue for Ewing sarcoma.
    Bone marrow transplantation, 2008, Volume: 42, Issue:11

    Topics: Combined Modality Therapy; Etoposide; Humans; Ifosfamide; Myeloablative Agonists; Neoplasm Metastasi

2008
Local and systemic control of Ewing's bone sarcoma family tumors of the ribs.
    Journal of surgical oncology, 2009, Sep-01, Volume: 100, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bone Plates; Chil

2009
Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer.
    British journal of cancer, 2009, Oct-06, Volume: 101, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Ifosfamide;

2009
Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:3

    Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docet

2010
Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cisplati

2011
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
    Brain tumor pathology, 2011, Volume: 28, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin

2011
Novel approaches to treatment of leiomyosarcomas.
    Current oncology reports, 2011, Volume: 13, Issue:4

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deox

2011
Sequential or concomitant chemotherapy in limited stage small-cell lung cancer.
    Swiss medical weekly, 2011, Volume: 141

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modali

2011
High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
    Oncology, 2011, Volume: 80, Issue:3-4

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Disease-Free Survival; Female; Human

2011
Maintenance therapy in the treatment of sarcoma.
    Clinical advances in hematology & oncology : H&O, 2011, Volume: 9, Issue:10

    Topics: Adolescent; Adult; Antineoplastic Agents; Child; Disease-Free Survival; Doxorubicin; Humans; Ifosfam

2011
Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl

2012
[Young man with severe back pain].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2012, Aug-07, Volume: 132, Issue:14

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diagnosis, Differe

2012
Evaluation of ifosfamide salvage therapy for metastatic canine osteosarcoma.
    Veterinary and comparative oncology, 2014, Volume: 12, Issue:4

    Topics: Amputation, Surgical; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothera

2014
Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
    Cancer, 2002, Sep-15, Volume: 95, Issue:6

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali

2002
[Pediatric rhabdomyosarcoma of the infratemporal fossa].
    Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris, 2002, Volume: 119, Issue:4

    Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Co

2002
A pilot study of short-course intensive multiagent chemotherapy in metastatic and axial skeletal osteosarcoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; C

2002
Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
    International journal of oncology, 2003, Volume: 22, Issue:3

    Topics: Adjuvants, Immunologic; Animals; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Cancer Vacci

2003
[Primary pulmonary synovial sarcoma: a report and diagnosis of 2 cases].
    Archivos de bronconeumologia, 2003, Volume: 39, Issue:3

    Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherap

2003
Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-15, Volume: 21, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Chil

2003
Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group.
    Oncology, 2003, Volume: 65, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisp

2003
Long-lasting complete remission of a patient with cervical cancer FIGO IVB treated by concomitant chemobrachyradiotherapy with ifosfamide and cisplatin and consolidation chemotherapy--a case report.
    European journal of gynaecological oncology, 2004, Volume: 25, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin;

2004
Hypersensitivity pneumonitis associated with the use of trofosfamide.
    Anti-cancer drugs, 2004, Volume: 15, Issue:6

    Topics: Administration, Oral; Aged; Alveolitis, Extrinsic Allergic; Antineoplastic Combined Chemotherapy Pro

2004
Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with Cisplatin-based chemotherapy.
    Medical oncology (Northwood, London, England), 2004, Volume: 21, Issue:3

    Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma.
    Bone, 2005, Volume: 37, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Remodeling; Caspases; Cell Line, Tumor

2005
Alveolar soft part sarcoma: a rare and enigmatic entity.
    Clinical orthopaedics and related research, 2005, Volume: 438

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophos

2005
Prognostic factors in pleuro-pulmonary blastoma.
    Pediatric blood & cancer, 2007, Volume: 48, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Child; Child, P

2007
[Comparing cisplatin plus etoposide with combination of mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer patients].
    Tuberkuloz ve toraks, 2006, Volume: 54, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide

2006
[Preoperative adjuvant therapy for primary malignant bone tumors].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Dactinomycin; Doxo

2007
[A case of recurrent metastatic testicular cancer, successfully treated with paclitaxel, ifomide and cisplatin].
    Hinyokika kiyo. Acta urologica Japonica, 2008, Volume: 54, Issue:1

    Topics: Adult; alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic

2008
Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; H

2008
[Chemotherapy of metastatic renal cell carcinoma with cis-diamminedichloroplatinum and other drugs].
    Hinyokika kiyo. Acta urologica Japonica, 1984, Volume: 30, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Renal Cell; Cispl

1984
[Treatment of pain caused by metastases of reactivated prostatic cancer with ifosfamide].
    Gan no rinsho. Japan journal of cancer clinics, 1983, Volume: 29, Issue:10

    Topics: Aged; Cyclophosphamide; Humans; Ifosfamide; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metast

1983
[Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide].
    Deutsche medizinische Wochenschrift (1946), 1983, May-27, Volume: 108, Issue:21

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophos

1983
The value of ifosfamide in the polychemotherapy of metastasized testicular cancer pretreated with chemotherapy.
    Arzneimittel-Forschung, 1982, Volume: 32, Issue:12

    Topics: Adolescent; Adult; Alkylating Agents; Cisplatin; Cyclophosphamide; Drug Therapy, Combination; Humans

1982
Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer.
    Human gene therapy, 1994, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter,

1994
[Extraosseous Ewing's sarcoma].
    RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 1995, Volume: 162, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dactinomycin; Diag

1995
Amendment to clinical research projects. Genetic marking with retroviral vectors to study the feasibility of stem cell gene transfer and the biology of hematopoietic reconstitution after autologous transplantation in multiple myeloma, chronic myelogenous
    Human gene therapy, 1993, Volume: 4, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Breast Neo

1993
High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.
    Cancer, 1995, Jul-01, Volume: 76, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Com

1995
Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas.
    Journal of chemotherapy (Florence, Italy), 1998, Volume: 10, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biot

1998
High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy.
    Bone marrow transplantation, 1999, Volume: 24, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carmustine; Ci

1999
First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Controlled Clinical Trials as

1999
Local therapy and other factors influencing site of relapse in patients with localised Ewing's sarcoma. United Kingdom Children's Cancer Study Group (UKCCSG).
    European journal of cancer (Oxford, England : 1990), 1999, Volume: 35, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo

1999
Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants. Rational individualization
    Cancer chemotherapy and pharmacology, 2001, Volume: 47, Issue:3

    Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents, Alkylating; Biomarke

2001
Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
    Medical and pediatric oncology, 2001, Volume: 36, Issue:1

    Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Mar

2001
[Concomitant radiochemotherapy for non-small-cell lung cancer: towards an ideal strategy].
    Revue des maladies respiratoires, 2001, Volume: 18, Issue:4 Pt 1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl

2001
[Cytostatic therapy of tumors under conditions of partial synchronisation with particular reference to malignant tumors of the testicle (author's transl)].
    MMW, Munchener medizinische Wochenschrift, 1975, Aug-22, Volume: 117, Issue:34

    Topics: Adult; Antineoplastic Agents; Bleomycin; Cell Transformation, Neoplastic; Child; Child, Preschool; D

1975
Chemotherapy in testicular tumors.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1977, Issue:60

    Topics: Bleomycin; Castration; Cell Division; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; D

1977
[Combined chemotherapy of metastasing melanoblastoma using ifosfamide and cis-platinum (II)-diamminodichloride (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1979, Jun-15, Volume: 104, Issue:24

    Topics: Adult; Aged; Cisplatin; Cyclophosphamide; Female; Humans; Ifosfamide; Male; Melanoma; Middle Aged; N

1979
[Clinical experiences with holoxan within the framework of sequential combination therapy (author's transl)].
    Medizinische Klinik, 1978, Sep-08, Volume: 73, Issue:36

    Topics: Adult; Aged; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Hodgkin Disease;

1978
Comparative effects of cyclophosphamide and isophosphamide on Lewis lung carcinoma.
    British journal of cancer, 1978, Volume: 38, Issue:5

    Topics: Animals; Cyclophosphamide; Dose-Response Relationship, Drug; Ifosfamide; Lung Neoplasms; Mice; Neopl

1978
Alternating non-cross-resistant chemotherapy for non-Hodgkin's lymphoma of intermediate-grade and high-grade malignancy. A pilot study.
    Cancer, 1992, Feb-01, Volume: 69, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclo

1992
Ewing's sarcoma: experience with 12 cases.
    Journal of chemotherapy (Florence, Italy), 1992, Volume: 4, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool;

1992
Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer.
    European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:5

    Topics: Adenocarcinoma; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm

1991
Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cis

1991
Ifosfamide in advanced adenocarcinoma of the oesophagus or oesophageal-gastric junction area. Rotterdam Esophageal Tumor Study Group.
    European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Ifosfam

1991
Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide.
    Onkologie, 1990, Volume: 13, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Dos

1990
Squamous cell carcinoma antigen and carcinoembryonic antigen levels as prognostic factors for the response of cervical carcinoma to chemotherapy.
    Gynecologic oncology, 1990, Volume: 38, Issue:1

    Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin;

1990
A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix.
    Cancer chemotherapy and pharmacology, 1990, Volume: 27, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr

1990
Treatment of metastatic breast cancer with the combination of ifosfamide, epirubicin and 5-fluorouracil.
    Cancer chemotherapy and pharmacology, 1990, Volume: 26 Suppl

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; F

1990
Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours.
    Cancer chemotherapy and pharmacology, 1990, Volume: 26 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance; Epirubicin; Femal

1990
Ifosfamide, methotrexate, and 5-fluorouracil in advanced pretreated breast cancer.
    Seminars in oncology, 1989, Volume: 16, Issue:1 Suppl 3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil;

1989
High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.
    Cancer, 1989, Apr-01, Volume: 63, Issue:7

    Topics: Adult; Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Ma

1989
Treatment of advanced malignancies with ifosfamide under protection with mesna.
    International journal of clinical pharmacology research, 1988, Volume: 8, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Male; Mesna

1988
Phase II study with ifosfamide in advanced malignant melanoma.
    Tumori, 1988, Apr-30, Volume: 74, Issue:2

    Topics: Adult; Drug Evaluation; Humans; Ifosfamide; Melanoma; Middle Aged; Neoplasm Metastasis

1988
Comparative studies on biological activity of /+/R and /-/S enantiomers of cyclophosphamide and ifosfamide. II. Antiproliferative activity of cyclophosphamide and ifosfamide enantiomers.
    Archivum immunologiae et therapiae experimentalis, 1986, Volume: 34, Issue:3

    Topics: Animals; Cyclophosphamide; Ifosfamide; Leukemia P388; Leukemia, Experimental; Lung Neoplasms; Mice;

1986
VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Humans; Ifosfamide; Kidn

1986